Schoeni Gilbert Edgar discloses 15.9% stake in Veraxa Biotech after business combination
Schoeni Gilbert Edgar filed a Schedule 13D disclosing beneficial ownership of 22,539,749 ordinary shares, representing 15.9% of Veraxa Biotech Holding AG's outstanding shares. The shares were acquired in connection with the closing of a business combination. Edgar is subject to a lock-up agreement restricting transfers for a specified period and may receive up to 5,000,000 additional earnout shares over three fiscal years if specified stock-price targets are met.
Key facts
- Schoeni Gilbert Edgar owns 22,539,749 ordinary shares (15.9% of class)
- Shares acquired in connection with business combination closing
- Lock-up agreement restricts transfers for specified period
- Earnout shares: up to 5,000,000 per fiscal year through December 31, 2028
- Earnout price targets: $11.00 VWAP by Dec. 31, 2026; $12.50 by Dec. 31, 2027; $14.00 by Dec. 31, 2028
Why it matters
Edgar's 15.9% stake and contractual lock-up signal a significant insider position tied to the business combination success, with potential for additional share dilution if earnout targets are met.
Share
Get the next chapter in your inbox — a Sentinel watches this company and briefs the next material filing the moment it lands.
Derived from SCHEDULE 13D filed 2026-06-15. Not investment advice. View the source filing on SEC.gov →